Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

cent in this year's second quarter to $34.8 million from $25.1 million in the same quarter a year ago. This growth is being driven by the expanded U.S. sales force for Seprafilm(R) adhesion barrier, which is helping to expand the product's use in gynecologic and colorectal surgery and C-section procedures.

Second-quarter revenue for the Genetics business increased 7 percent to $78.5 million from $73.7 million. This growth was driven in part by the continuing demand for prenatal screening for genetic conditions. Additionally, Genzyme experienced increased demand for its KRAS mutation testing for colorectal cancer, as recent studies have shown that identifying KRAS mutations can assist oncologists in selecting treatment for patients with colorectal cancer. This increasing recognition of the value of diagnostics in personalized medicine will continue to fuel organic growth in the Genetics business.

Oncology revenue rose in the second quarter to $33.3 million from $17.4 million based on increasing sales of Clolar and Campath(R) (alemtuzumab). The increase also reflects the addition of European sales of Clolar, which Genzyme began recording following its acquisition of Bioenvision Inc. late last year. Genzyme is working to introduce Clolar worldwide as well as expand its indications. The product is currently approved in the United States and Europe as a third-line treatment for pediatric patients with acute lymphoblastic leukemia. Genzyme is developing Clolar for use globally as a first-line therapy for adult AML and myelodysplastic syndromes, significantly larger indications that the company estimates will drive peak annual sales of the product to approximately $600 million. Last month, Genzyme reported encouraging results from its pivotal CLASSIC II trial evaluating the use of Clolar to treat older adult patients with acute myeloid leukemia. Oncology revenue also reflects growing first-line use of Campath in the treatment of patients with B-cell chronic l
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... companies release latest developments, patents and results of studies ... GNSZ), Eli Lilly and Company (NYSE: LLY ... Celgene Corporation (NASDAQ: CELG ) and Arena ... GNSZ), a leader in developing prodrug therapeutics for the ...
(Date:9/19/2014)... 2014 , The first grants ... Paediatric Endocrinology (ESPE) Meeting  Investment supports innovative ... in the field of growth  , EMD ... Germany , today announced the first recipients of ... awards were announced during a Satellite Symposium organized by ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... CITY, April 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, will announce ... market open on Wednesday, May 6, 2009. The Company ... these results later that same day at 3:30 p.m., ...
... April 30 Medarex, Inc. (Nasdaq: MEDX ) ... 31, 2009. Medarex,s net loss for the quarter ended March ... the same period in 2008, Medarex,s net income of $103.3 ... million, or $1.19 per share, from the sale of 2.5 ...
... of its fifth Best Practices Awards program. Grand Prize winners ... Broad Institute of MIT and Harvard, Genedata, Genentech, GlaxoSmithKline, Merck & ... Research. , ... Needham, Mass (PRWEB) April 29, 2009 ...
Cached Biology Technology:Medarex Announces 2009 First Quarter Financial Results 2Medarex Announces 2009 First Quarter Financial Results 3Medarex Announces 2009 First Quarter Financial Results 4Medarex Announces 2009 First Quarter Financial Results 5Medarex Announces 2009 First Quarter Financial Results 6Medarex Announces 2009 First Quarter Financial Results 7Medarex Announces 2009 First Quarter Financial Results 8Medarex Announces 2009 First Quarter Financial Results 9Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 2Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 3Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 4Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 5Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 6
(Date:9/19/2014)... The sense of fairness did not evolve for the ... reap the benefits of continued cooperation, so say Frans ... a review article about inequity aversion (IA), which is ... review is published in Science . , ... 35 IA-related studies to address their hypothesis that it ...
(Date:9/18/2014)... GSA Bulletin study uses tree rings to ... Chaco Wash in northern New Mexico, USA. By determining ... willow, investigators were able to precisely date arroyo sedimentary ... this data with aerial imagery, LiDAR, longitudinal profiles, and ... , Arroyos are deep, oversized channels that have vertical ...
(Date:9/18/2014)... University and the Quebec government have discovered microplastics ... Journal of Fisheries and Aquatic Sciences . , ... or industrial cleansers, to which they are commonly ... and buoyancy, they may readily pass through sewage ... in the world,s oceans, but have only recently ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Microplastic pollution discovered in St. Lawrence River sediments 2
... Oct. 12 Stayhealthy, Inc. an innovative, privately ... measurement, announced that it will join Hooper Holmes ... prevention and chronic care management October 13-15 to ... decision makers. Earlier this year, Stayhealthy announced the ...
... countries now acknowledge the need to obtain their energy ... will explain how his team have developed a new ... as 25 wind turbines. These reactors use a consortium ... crops to produce biogas (a mixture of methane and ...
... maintain bumblebee populations by growing plants with red flowers or ... of the common snapdragon, Antirrhinum majus , at the ... important pollinators of crops as well as the plants in ... BBSRC, is committed to research that can benefit agriculture and ...
Cached Biology News:Stayhealthy® Joins Hooper Holmes to Provide Complimentary Web-Based Biometric Screenings to All Participants at Care Continuum Alliance Conference 2Stayhealthy® Joins Hooper Holmes to Provide Complimentary Web-Based Biometric Screenings to All Participants at Care Continuum Alliance Conference 3Stayhealthy® Joins Hooper Holmes to Provide Complimentary Web-Based Biometric Screenings to All Participants at Care Continuum Alliance Conference 4Microscopic solutions to world's biggest problems 2Landing lights for bumblebees 2
...
Human Presenilin-2 NTF Affinity Purified Polyclonal Ab...
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
Human Glypican 2 Biotinylated Affinity Purified PAb...
Biology Products: